SION — Sionna Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2036042 ·
Last close
$3.07
Market Cap
$138.87M
52W High
$54.97
52W Low
$2.99
ADV30
887,941
Next earnings
2026-11-10
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -34,819,000 -32,418,000 263,261,000 83,878,000 22,737,000
Jun 2026 0 — -32,470,000 -29,886,000 283,249,000 63,322,000 17,474,000
Mar 2026 0 — -29,599,000 -26,779,000 305,039,000 63,324,000 16,831,000
Dec 2025 0 — -23,612,000 -20,440,000 325,953,000 58,451,000 19,120,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-79,409,000
Investing CF
$107,823,000
Financing CF
$4,634,000
CapEx
$-377,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.44
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-345,437,000
Inventory
—
Receivables
—
ST Investments
$140,709,000
EBIT TTM
$-120,500,000
Pretax Income TTM
$-109,523,000
Interest Exp TTM
—
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -88,982,000 -75,268,000 325,953,000 19,120,000 306,833,000 -66,297,000
Dec 2024 0 -70,556,000 -61,688,000 185,752,000 349,465,000 -163,713,000 -52,787,000
Dec 2023 0 -50,333,000 -47,263,000 51,945,000 166,826,000 -114,881,000 -43,699,000
Dec 2022 0 -41,372,000 -40,240,000 87,369,000 157,293,000 -69,924,000 -36,068,000

TTM Snapshot

Revenues TTM
$12,035,000
NetIncome TTM
$-97,383,000
OpCashFlow TTM
—
Assets (Latest)
$283,249,000
Forward EPS
$-2.31

Max Pain — expiry 2027-01-15

max pain strike: $5.00 · spot: $2.97 · call oi: 302 · put oi: 8,391
Expected Move to 2027-01-15: ±$2.02 (68.18%) — implied range $0.95 – $5.00 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALXO ALX ONCOLOGY HOLDINGS INC $138.97M $1.00 —
RNA Atrium Therapeutics, Inc. $139.78M $6.48 —
MENS Jyong Biotech Ltd. $133.62M $1.80 —
ZNTL Zentalis Pharmaceuticals, Inc. $146.42M $1.49 —
MSLE Satellos Bioscience Inc. $131.54M $6.20 —

News headlines (Yahoo Finance, 1h cache)

Sionna Therapeutics Reports Third Quarter 2026 Financial Results
2026-11-10 12:00 · Yahoo
Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-10-12 12:35 · Yahoo
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
2026-10-08 20:30 · Yahoo
Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?
2026-09-17 21:21 · Yahoo
FDA clears first generic radioligand drug; Sionna turns to layoffs
2026-09-15 17:13 · Yahoo
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
2026-09-14 20:01 · Yahoo
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?
2026-08-13 09:11 · Yahoo
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?
2026-08-13 05:13 · Yahoo
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall
2026-08-12 10:12 · Yahoo
Sionna Therapeutics stock falls 92% after SION-719 trial failure
2026-08-11 13:11 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.